AIDX · 20/20 Biolabs, Inc.
$0.35
+0.00 (+0.71%)
At close · Oct 6
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“The accompanying condensed financial statements have been prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The accompanying condensed financial statements do not include any adjustments relating to the recoverability and classification of assets and their carrying amounts, or the amounts and classification of liabilities that may result should the Company be unable to continue as a going concern. If the Company is unable to obtain adequate capital, it could be forced to cease operations.”View the 10-Q filed Aug 14, 2026
Market Cap
$5.31M
Shares
12.77M
Volume · Oct 6
69.11K
Avg daily vol (3M)
92.44K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$0.35
Open$0.35
Day$0.34–0.36
Available close range$0.35–23.85
Avg vol 30d63K
Short int47K · 0.4% float · 1.0d
Short vol20%
DataFeb 2026–Oct 2026
Filing10-Q · Aug 14
The closing range uses available history since Feb 19, 2026; less than a full year is stored.
Up next
filed Aug 14, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$2.04M
Trailing 12 months
Net income (TTM)
−$5.81M
Trailing 12 months
Revenue growth YoY
+36.5%
Year over year
Operating margin
-215.7%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$4.55M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+123.7%
Year over year · more shares
Price change (1Y)
—
Trailing year
Short interest
0.4%
Latest settlement · 1.0 days to cover
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Sell
Momentum
Very Weak
Sentiment
Bullish
Fundamentals
Excellent
Quant / Vol
Very High
Market backdrop
VIX 15 · calm
Equity put/call 0.57
Technical
price trend
50 / 200-day cross
No cross
Price vs 50-day avg
−28%
below
RSI (14)
28
oversold
MACD trend
Negative
52-week position
0%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−39%
trailing
6-month return
−80%
trailing
Relative strength
−91%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50/200-day averages unavailable
Institutional flow
Accumulating
+114% holders QoQ · +10 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
0.37% of float · ▼ -50.4% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
15 holders — 13F breadth
Squeeze score
31
low risk · 0–100
Fundamentals
Revenue growth
+17%
Y/Y
Gross margin
30%
expanding
EPS growth
+34%
Y/Y
Quant / Vol
risk profile
Volatility
131%
annualized · 1-yr
Max drawdown
−99%
past year
ATR
14.8%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 50-day avg
−28%
Bearish
RSI (14)
28
Neutral
MACD trend
Negative
Bearish
52-week position
0%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50/200-day averages unavailable
Institutional flow
Accumulating
+114% holders QoQ · +10 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
0.37% of float · ▼ -50.4% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
15 holders — 13F breadth
Price context
position in its available closing range
Range low $0
Now $0 · 0%
Range high $24
vs 50-day avg -28%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Maryland fire departments awarded for OneTest™ cancer screenings | $520,000 | Q2 2026 | — |
| New accounts orders received | 29 | Q2 2026 | — |
| OneTest™ Revenue (as % of total revenue) | 95.3% | Q2 2026 | — |
| Vermont firefighter program screening capacity | 4,500 | FY2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
AIDX
this stock
20/20 Biolabs, Inc.
|
$5.31M | — | +16.7% | — | 0.4% |
|
ABT
Abbott Laboratories
|
$174.90B | -21.7% | +5.7% | 28.1 | 1.1% |
|
MDT
Medtronic plc
|
$113.38B | -9.3% | +8.4% | 21.8 | 1.3% |
|
SYK
Stryker Corp
|
$104.47B | -20.8% | +11.2% | 28.2 | 2.0% |
|
BSX
Boston Scientific Corp
|
$63.59B | -55.8% | +12.5% | 17.8 | 3.2% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| AIDX | -14.0% | -39.2% | -79.7% | -19.9% | — |
| SPY | +2.0% | +1.7% | +11.3% | +2.2% | +14.3% |
| vs SPY | -16.0% | -40.9% | -91.1% | -22.1% | — |